AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03235986
Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
Trial: NCT03235986
Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
Trial: NCT01871922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT03163667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT03163667
Drug: CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT02082977
Drug: GSK2816126
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
Trial: NCT01758120
Drug: prednisone plus cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control
Trial: NCT00236041
Drug: ACTIQ®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02871440
Drug: Optive
RxNorm normalized name: optive
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03202303
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of 10 mg/kg/day of placebo
Trial: NCT01489137
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml.
Trial: NCT00319007
Drug: Sulindac (drug)
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00319007
Drug: VSL#3 (probiotic)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01241123
Drug: Sitz-Markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiopaque markers to subjectively follow the return of bowel function
Trial: NCT02115529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
Trial: NCT02033941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
Trial: NCT01275300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00663260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Once Daily, 104 weeks
Trial: NCT01442610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1tablet once daily for 8 weeks
Trial: NCT00330733
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were randomized to 12-week treatment with up to 4 g/day.
Trial: NCT00330733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were randomized to 12-week treatment matching the active salsalate arm.
Trial: NCT01979185
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00980798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet once daily for 16 weeks
Trial: NCT03879798
Drug: DS-3201b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg daily
Trial: NCT01613586
Drug: ASP3652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01613586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03863574
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Trial: NCT04017208
Drug: ASP2713
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04017208
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT03260322
Drug: ASP8374
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT03809351
Drug: [F-18]AV-1451-PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
Trial: NCT04278781
Drug: AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
Trial: NCT00666042
Drug: Vigamox - administration in spray form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigamox will be administered in a spray form
Trial: NCT00666042
Drug: Vigamox eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigamox eye drops
Trial: NCT01374854
Drug: traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exogenous insulin injection daily
Trial: NCT02542215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral spray
Trial: NCT02542215
Drug: Standard Care - Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
Trial: NCT03503331
Drug: [C-11]PiB-PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
Trial: NCT00963287
Drug: bascial prescription plus or minus herbs depend on symptoms
RxNorm normalized name: Arctium minus root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoction ,two times a day
Trial: NCT02402309
Drug: Active topical NS2 1% dermatologic cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02402309
Drug: Vehicle placebo 0.0% NS2 dermatologic cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01225575
Drug: co.don chondrosphere®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect
Trial: NCT02248493
Drug: Placebo (for paracetamol)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248493
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04265274
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosing 400mg daily
Trial: NCT00889330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle without active, one drop in each eye at each of two visits.
Trial: NCT00833703
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Trial: NCT02063854
Drug: NE-58095 IR Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NE-58095 IR placebo-matching tablets
Trial: NCT02063854
Drug: NE-58095 DR Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NE-58095 DR placebo-matching tablets
Trial: NCT01053611
Drug: propofol + remifentanil 0 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 0 ng/ml
Trial: NCT01053611
Drug: propofol + remifentanil 2 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00751231
Drug: PRT060128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
Trial: NCT01053611
Drug: propofol + remifentanil 4 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01053611
Drug: propofol + remifentanil 6 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01053611
Drug: propofol + remifentanil 0 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01055340
Drug: Oxyntomodulin (OXM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single infusion of OXM 3.0 pmol/kg/min by IV
Trial: NCT01055340
Drug: Comparator: Oxyntomodulin (OXM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single infusion of OXM 0.6 pmol/kg/min by IV
Trial: NCT01055340
Drug: Comparator: Placebo [ hemaccel-containing saline]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Placebo infusion of hemaccel-containing saline by IV
Trial: NCT01537432
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT03682367
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of sugar-free Placebo peri- and post-operatively.
Trial: NCT04305210
Drug: F-18 PMPBB3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
Trial: NCT00421564
Drug: DBT-Danggui Buxue Tang
RxNorm normalized name: Buxus sempervirens leafy twig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00654602
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02014467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT00900614
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
Trial: NCT01511302
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNS60, 2ml, nebulized twice daily.
Trial: NCT01511302
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline placebo, 2 ml, nebulized twice daily.
Trial: NCT00480532
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
Trial: NCT00480532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
Trial: NCT00480532
Drug: Doxycycline 100bid x5 days at the time of bleeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
Trial: NCT00480532
Drug: Subantimicrobial doxycycline daily
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
Trial: NCT00480532
Drug: placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for the first 84 days of the study
Trial: NCT03524157
Drug: PRO-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
Trial: NCT03524157
Drug: Xyel Ofteno
RxNorm normalized name: Nazil Ofteno 0.02 % Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
Trial: NCT00784017
Drug: recombinant asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
Trial: NCT00659022
Drug: neoadjuvant treatment with capecitabine and oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
Trial: NCT00710619
Drug: Feiba VH
RxNorm normalized name: Feiba VH Immuno
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
Trial: NCT00011635
Drug: Silymarin (milk thistle)
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01514357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
Trial: NCT03421353
Drug: AZD9150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement.
Trial: NCT03421353
Drug: 5-Flourouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
Trial: NCT02886962
Drug: Oral anticoagulation with vitamin K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week
Trial: NCT04318938
Drug: Tyrosine kinase inhibitor
RxNorm normalized name: Protein-tyrosine kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with any TKI
Trial: NCT04501120
Drug: standard-dose HHT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
Trial: NCT00413712
Drug: Calcium Channel Blocker & Adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04391569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT00829868
Drug: SONATA® 10 mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg
Trial: NCT01446523
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup, 30 ml BD for 3 months in Gr. NL
Trial: NCT01241500
Drug: ON 01910.Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
Trial: NCT00061711
Drug: Multibotanical phytoestrogen formula
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01362790
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
Trial: NCT02038647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching tablets
Trial: NCT04728425
Drug: subcutaneous immunoglobulin (SCIG)
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% subcutaneous immunoglobulin
Trial: NCT04728425
Drug: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
Trial: NCT00044785
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00044785
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03598348
Drug: Apatinib+Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
Trial: NCT02444260
Drug: Bupivocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
Trial: NCT00725855
Drug: Placebo for MEM 3454
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose
Trial: NCT00386581
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03935347
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02304185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
Trial: NCT01408030
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9%, 0.1 ml spray in each nostril bid
Trial: NCT04233892
Drug: Collagen/BMMNCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
Trial: NCT00938574
Drug: Atu027
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00925574
Drug: CNTO 1959; Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01408030
Drug: Estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
Trial: NCT03524066
Drug: Inhalation
RxNorm normalized name: INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
Trial: NCT03524066
Drug: Systemic
RxNorm normalized name: Fluorouracil, Systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
Trial: NCT01096121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose
Trial: NCT03437720
Drug: SAR425899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection
Trial: NCT03437720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection
Trial: NCT02280850
Drug: Guanxin Shutong Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT02280850
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules three times a day; Duration: 4 weeks.
Trial: NCT02496000
Drug: ORMD-0801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Insulin
Trial: NCT02496000
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01111552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug matching placebo capsule.
Trial: NCT02796911
Drug: Xenograft
RxNorm normalized name: Xenograft heart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
Trial: NCT02796911
Drug: Bioactive glass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).